LY3007113

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3007113, covering 2018-08-07 to 2018-08-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3007113 in Participants With Advanced Cancer [Phase 1]